Další formáty:
BibTeX
LaTeX
RIS
@proceedings{989259, author = {Kolek, V. and Grygárková, I. and Chalupa, J. and Koubková, L. and Švecová, J. and Skřičková, Jana and Ostřížková, L. and Sixtová, D.}, booktitle = {13th Central European Lung Cancer Conference}, doi = {http://dx.doi.org/10.1016/j.lungcan.2012.05.063}, keywords = {lung cancer; erlotinib}, language = {eng}, title = {Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemotherapy of non-small cell lung cancer: A prospective multicentre study of feasibility, tolerability and 3-year survival}, year = {2012} }
TY - CONF ID - 989259 AU - Kolek, V. - Grygárková, I. - Chalupa, J. - Koubková, L. - Švecová, J. - Skřičková, Jana - Ostřížková, L. - Sixtová, D. PY - 2012 TI - Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemotherapy of non-small cell lung cancer: A prospective multicentre study of feasibility, tolerability and 3-year survival KW - lung cancer KW - erlotinib N2 - Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non small-cell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients. ER -
KOLEK, V., I. GRYGÁRKOVÁ, J. CHALUPA, L. KOUBKOVÁ, J. ŠVECOVÁ, Jana SKŘIČKOVÁ, L. OSTŘÍŽKOVÁ a D. SIXTOVÁ. Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemotherapy of non-small cell lung cancer: A prospective multicentre study of feasibility, tolerability and 3-year survival. In \textit{13th Central European Lung Cancer Conference}. ISSN~0169-5002. doi:10.1016/j.lungcan.2012.05.063. 2012.
|